A Randomized Phase II Study of MEDI0680 in Combination with Durvalumab versus Nivolumab Monotherapy in Patients with Advanced or Metastatic Clear-cell Renal Cell Carcinoma.
Martin H VossArun A AzadAaron Richard HansenJhanelle E GraySarah J WelshXuyang SongMichael KuzioraLina MeineckeJorge M BlandoIkbel AchourYi WangFarzana L WalcottSjoukje F OostingPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2022)
MEDI0680 combined with durvalumab was safe and tolerable; however, it did not improve efficacy versus nivolumab monotherapy.